Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
Improved Survival with Bevacizumab in Advanced Cervical Cancer | NEJM
Avastin® (bevacizumab) Clinical Trials | CC Treatment
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Avastin® (bevacizumab) Clinical Trials | MRCC Treatment
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
Bevacizumab Misses Mark in Untreated Metastatic Bladder Cancer | MedPage Today
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study | Anticancer Research
Cancers | Free Full-Text | Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma - The ASCO Post
When more is better: bevacizumab treatment for patients with ovarian cancer
Bevacizumab and chemotherapy for recurrent glioblastoma | Neurology
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
